Research

Hormonal

Insulin-sensitizing agents (DPP4 inhibitors, SGLT2 inhibitors, GLP-1 analogues) reduce atherosclerosis risk by modulating perivascular adipose tissue (PVAT) biology, specifically by reducing inflammatory adipokines like ceramides and restoring vascular insulin sensitivity.

If you have obesity and heart risk, medications like GLP-1 analogues (e.g., liraglutide) can help your heart vessels directly, not just by helping you lose weight. They reduce harmful fats (ceramides) in your blood that cause inflammation around your arteries. This happens even if your weight doesn't change much, showing that these drugs protect your heart independently of weight loss.

GoodSupportsHIGH confidence
compounds with insulin-sensitising effects offer an important paradigm for identifying novel therapeutic targets in atherosclerosis... liraglutide... was demonstrated to mitigate the significant increase in plasma CerC16 and its glycosylated derivative C16:0-glucosylceramide (GlcC16) seen in a control group on a low-calorie diet
Murray Polkinghorne et al. · CardioMetabolic Syndrome Journal · 2022

Why this rating

Supported by mechanistic studies, metabolomics, and a 52-week randomized trial.

Source

The Role of Perivascular Fat in the Diagnosis and Prognosis of Atherosclerosis

Murray Polkinghorne et al. · CardioMetabolic Syndrome Journal · 2022

DOI 10.51789/cmsj.2023.3.e1

narrative_reviewCited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →